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Introduction 
 
Academic medical centers (AMCs) form the intellectual core of medicine, training 
future doctors and researchers, and establishing standards that guide practicing 
physicians in the wider community. Where pharmaceutical industry marketing 
conflicts with the goals of patient care and professionalism, AMCs can provide 
leadership and guidance by establishing new standards on physician-industry 
relationships. 
 
I.  The Problem  
 
The pharmaceutical industry spends more than $25 billion each year in direct 
marketing to physicians, including more than $7 billion for detailing and journal 
advertising and $18 billion for samples.
1  Ninety thousand sales representatives are 
deployed.
2  Many promote new and expensive products that lack clear therapeutic 
advantage and may have unknown adverse effects.
3  Industry representatives often 
gain access to doctors by offering meals, drug samples and other gifts. This intense 
marketing is widely believed to undermine quality of care and increase costs to 
patients, public programs, health care institutions, health insurers and employers.
4-6  
 
Gifts generate conflicts of interest. Physicians who accept company gifts may feel a 
need, subconscious or otherwise, to reciprocate.
7 Even small gifts change behavior;
7  
public records show that many clinicians receive tens of thousands of dollars per 
year from the industry.
8   
 
Industry sales representatives frequently provide inaccurate information (reviewed 
in Molloy et al.).
9  Yet contact with sales representatives or acceptance of industry 
support leads to increased prescribing of the funders’ products, increased requests 
for formulary inclusion and decreased use of generic medications.
3, 10  Nearly all 
physicians (more than 90 percent) have some relationship with industry,
11  but 
many often fail to realize the extent to which these relationships influence their own 
prescribing decisions.
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Relationships between medicine and industry also exist at the institutional level. Many AMCs depend heavily on 
pharmaceutical company support for research, education and other organizational activities.
15 Positive 
relationships with industry may confer institutional benefits, but the attendant conflicts of interest must be 
addressed.   
 
II. Setting new standards  
In January 2006, a group of leading physicians and researchers from the Institute of Medicine as a Profession 
(IMAP) and the American Board of Internal Medicine Foundation called for AMCs to take the lead in ending 
conflicts of interest between physicians and pharmaceutical companies. Writing in the Journal of the American 
Medical Association (JAMA), the authors outlined several recommendations toward change.
16  The article 
generated a great deal of interest in the press and from within the medical profession.
17-22  Following its 
publication, a number of AMCs strengthened their policies.  The Prescription Project was launched by The Pew 
Charitable Trusts in February 2007 with a major goal of promoting the JAMA recommendations. 
To assess current conflict of interest policies at—and recommend “best practices” for— AMCs, the Prescription 
Project conducted an in-depth investigation of policies, or draft policies, at a number of leading AMCs. Using 
online research and interviews, we collected information on policies as well as implementation histories, 
successes, failures, and future plans.  Drawing on the JAMA recommendations, we used the following specific 
criteria for assessing policies: 
   
1.   Gifting:  Do AMCs permit gifts to physicians from industry?  Are there any restrictions on “giveaway” 
items, meals, payment for travel to, or time at, meetings, or payment for CME participation?   
 
2.   Drug samples:  Do AMCs permit physicians to accept samples?  Or is there a system (e.g. vouchers 
for low-income patients) that distances the company from the physician?  Are samples limited to 
patient use, or may physicians use samples for themselves and their families?   
 
3.   Drug formularies:  Do AMCs permit physicians with financial ties to drug companies to serve on 
committees overseeing formularies or the purchase of medical devices?     
 
4.   Continuing medical education (CME):  How do AMCs manage industry funds for CME?  What 
policies are in place to ensure that CME events remain free of influence from donors? 
 
5.   Funds for physician travel:  Do AMCs permit manufacturers to directly fund travel of faculty and 
trainees?  What policies govern funds for physician travel?    
 
6.   Speakers bureaus and ghostwriting:  Do AMCs allow faculty to serve on speakers bureaus or to 
publish articles or editorials that are ghostwritten by companies?  
 
7.   Consulting and research grants:  How do AMCs oversee grants for consulting and research?  Do 
they require an explicit contract with specific deliverables?  Do they allow “no strings attached” grants 
and gifts to individual researchers? 
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III.   Progress toward best practices 
 
In the 18 months since the publication of the JAMA recommendations, more than a dozen AMCs around the 
country have responded to the call to adopt more stringent regulations.   
 
The Prescription Project has been actively engaged with leaders at AMCs, including the University of California, 
Los Angeles and the University of Massachusetts, as well as the institutions mentioned in Table 1. We have 
assisted a number of these centers in drafting and implementing new policies.  We are also working with select 
AMCs to conduct in-depth case studies that will provide new insights for institutions and leaders nationally. 
 
Following are “best policies” in each of the issue areas addressed in the JAMA recommendations. Leaders at other 
AMCs can use these exemplary policies to begin discussions with faculty and staff about the importance and 
feasibility of strengthening existing regulations. Doing so will improve patient care and protect the integrity of 
medical decision-making by reducing the influence of industry marketing on prescribing patterns.   
 
Table 1: Examples of model policies 
 
Issue Area  Academic Medical Center  Exemplary Policy 
Gifts Kaiser  Permanente,   
Veterans Affairs  
Physicians may not accept any form of personal gift 
from industry or its representatives. 
Meals  University of Wisconsin, 
University of Pittsburgh 
Food or drink may not be provided by any vendor. 
Samples  University of Michigan  Sample medications are not permitted in University 
of Michigan Hospitals and Health Centers (UMHHC), 
including both patient and non-patient areas. Under 
special circumstances, in which there is a legitimate 
clinical need, with the approval noted below, 
sample medications may be permitted in UMHHC.  
Specific requests to have physical samples in 
UMHHC clinics must be made on the Special Cause 
sample request form, and be approved by the 
Ambulatory Formulary Committee and the site 
medical director. 
Pharmaceutical 
representative 
access to 
physicians  
University of Pennsylvania, 
Boston University School of 
Medicine/Boston Medical Center 
Pharmaceutical representatives are forbidden from 
patient areas.  University of Pennsylvania’s policies 
are very detailed, requiring representatives to 
register and schedule appointments to see 
physicians in their offices.   
BUSM/BMC does not permit interns, residents and 
other trainees to meet with sales representatives. ACADEMIC MEDICAL CENTERS  •  SEPTEMBER 1, 2007   
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Issue Area  Academic Medical Center  Exemplary Policy 
Formularies  Yale University  Yale Medical Group physicians who are involved in 
institutional decisions concerning the purchase of 
or approval of medications or equipment, or the 
negotiation of other contractual relationships with 
industry, must not have any financial interest (e.g., 
equity ownership, compensated positions on 
advisory boards, a paid consultancy or other forms 
of compensated relationship) in pharmaceutical 
companies that might benefit from the institutional 
decision. Indirect ownership through mutual funds 
is acceptable. 
Continuing 
Medical 
Education 
University of California at Davis  Industry support for continuing medical education 
goes into a central repository, and not directly (or 
indirectly, through a subsidiary agency) to an 
Accreditation Council for Continuing Medical 
Education (ACCME)-accredited program.   
Scholarships 
and Fellowships 
Stanford University  
 
 
Industry-supported scholarships go directly to the 
department or division, and not to the individual.  
The department or division is required to verify the 
educational merits of the conference or program for 
which the student receives funding. 
Consulting and 
Honoraria 
University of Washington  University of Washington staff, like other state 
employees, may not receive honoraria, unless 
specifically authorized by the agency where they 
serve. An employee may not receive anything of 
economic value under any contract or grant outside 
of his or her official duties. 
 
 
IV. External threats… and internal barriers   
Public pressure for controlling conflicts of interest is growing. The national press reports regularly on the dangers 
and cost to patients of drug industry influence on physician decisions. Some states, including Vermont, Minnesota 
and Maine, have already passed laws limiting gifts to physicians or requiring public disclosure, while several 
Attorneys General have initiated or joined cases against potentially illegal relationships between pharmaceutical 
companies and physicians.
23-25 Washington, D.C. lawmakers are also considering action. Congressman Peter 
DeFazio (D-Ore) has introduced a bill requiring drug and device companies to disclose marketing and promotional 
gifts given to doctors.
26  Senator Chuck Grassley (R-IA) has introduced a similar measure,
27  and the Senate 
Finance Committee has begun investigating the extent of pharmaceutical industry influence over continuing 
medical education content.
28, 29  The Senate Aging Committee is also examining the influence of pharmaceutical 
industry marketing on medicine.
 30 
 
 
Although some AMCs have begun to address these issues, the national landscape remains relatively unchanged. 
Through our discussions with AMC leaders, we have identified a number of barriers to moving ahead, and are 
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Barriers to Change  Strategies to Promote Improvement 
Institutional dependency on drug 
industry funding for core functions, 
such as research, as well as ancillary 
support.   
Organizations need to identify the extent of the support and how 
to compensate for its loss.  For example, the University of 
Michigan has implemented programs for medical residents to 
ease the transition away from an estimated $2 million in 
industry-sponsored meals.   
 
Ignorance of what other AMCs are 
doing about conflict of interest.  
Even organizations with more stringent 
policies were sometimes unaware of 
potential resources. 
 
The Prescription Project is facilitating communication between 
institutions and serves as an information resource for AMCs. 
Decentralized hospital/educational 
structure.  A complex organizational 
structure complicates the process of 
policy change.   
The Prescription Project is creating toolkits to provide AMCs in 
this position with concrete examples of how other institutions 
have overcome this challenge.  
 
Fear of faculty resistance.  Many 
institutions worry that eliminating gifts 
will anger faculty or prompt them to 
leave. 
Our preliminary investigations have shown that appealing to the 
faculty’s sense of responsibility as members of a prestigious 
institution can motivate faculty members to demonstrate 
professionalism and leadership by giving up industry perks. The 
Prescription Project also provides resources to educate the 
profession on the effects of industry marketing. 
Over-reliance on disclosure.  
Institutions without firm policies may 
contend that disclosure is a sufficient 
response. 
 
Disclosure eliminates neither conflicts of interest, nor their 
negative consequences. 
Inadequate implementation.  Some 
may believe it is impossible to police 
faculty behavior; that forbidden 
activities will simply move off-campus; 
or that AMC policies do not matter 
because most physicians work at 
multiple clinical sites. 
Cultural change will not occur unless policies are accompanied by 
a commitment to implementation. Our work with AMCs suggests 
that formal policing may not be as crucial as educational 
initiatives. The Prescription Project is creating program guides 
and training to promote change.    
 
 
As more AMCs strengthen their guidelines, some of these barriers will disappear. Industry threats to withdraw 
funding from stringent AMCs will lose effectiveness, and fears of competition for faculty will weaken.  ACADEMIC MEDICAL CENTERS  •  SEPTEMBER 1, 2007   
  6 
 
 
V. Call to Action: Two Parts 
 
Overcoming barriers and creating momentum for change requires leaders in the profession to think differently 
about conflict of interest. If the medical profession does not act, it will lose its prerogative.  
 
We urge the Association of American Medical Colleges (AAMC) to provide leadership on these issues across 
all medical schools and teaching hospitals in the United States. The AAMC has convened a task force dedicated to 
this issue. To fulfill the AAMC mission of “strengthening the quality of medical education and improving the 
nation's health by enhancing the effectiveness of academic medicine,” the organization must now promote a 
national agenda and a level playing field.  
 
The AAMC should:  
•  Exert leadership by strengthening its guidelines related to conflict of interest 
•  Provide assistance to member AMCs so they can implement effective reforms 
•  Create an oversight committee to evaluate the actions of member organizations. 
 
While the AAMC needs to provide overall guidance, it will be individual AMCs that determine the ultimate success 
or failure of efforts to eliminate conflicts of interest. Therefore, we call on all academic medical centers to: 
•  Examine best practices at other institutions, including those mentioned 
•  Assess current policies on conflict of interest  
•  Engage faculty broadly to build commitment at all levels   
•  Address key issues and announce the new policies to the professional and broader communities 
•  Enforce adherence through an effective monitoring system. 
 
Conclusion 
The medical profession and the public look to AMCs for leadership. New standards must demonstrate the 
importance of evidence-based practice, free from industry influence and bias. The Prescription Project is assisting 
AMCs by facilitating communication, providing toolkits and developing concrete and effective best-practice 
recommendations.  
 
Strong standards will advance patient well-being and free physicians from conflicts of interest. Now is the time for 
action.  
 
The Prescription Project (RxP), led by Community Catalyst and the Institute on Medicine as a 
Profession and funded by The Pew Charitable Trusts, seeks to eliminate conflicts of interest created 
by industry marketing by promoting policy change among academic medical centers, professional 
medical societies and public and private payers.  The Prescription Project has spent the past six 
months working closely with academic medical centers to investigate their current polices and 
promote best practices among them. ACADEMIC MEDICAL CENTERS  •  SEPTEMBER 1, 2007   
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